Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2005-08-02
2005-08-02
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
C514S717000, C560S008000, C560S019000, C560S039000, C560S075000
Reexamination Certificate
active
06924314
ABSTRACT:
Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
REFERENCES:
patent: 4011321 (1977-03-01), Coates et al.
patent: 4098816 (1978-07-01), Thorne et al.
patent: 4638094 (1987-01-01), Nakai et al.
patent: 4845231 (1989-07-01), Kees
patent: 5817693 (1998-10-01), Cousins et al.
patent: 5948803 (1999-09-01), Maeda et al.
patent: 6555536 (2003-04-01), Burris et al.
patent: 9802163 (2000-11-01), None
patent: 1929165 (1969-12-01), None
patent: 2 309 986 (1974-08-01), None
patent: 2459468 (1975-07-01), None
patent: 2512673 (1975-10-01), None
patent: 2527066 (1976-01-01), None
patent: 3012012 (1981-10-01), None
patent: 71399 (1983-02-01), None
patent: 288190 (1992-07-01), None
patent: 407891 (1993-06-01), None
patent: 393400 (1994-12-01), None
patent: 2191887 (1975-08-01), None
patent: 1488330 (1977-10-01), None
patent: 47025149 (1972-10-01), None
patent: 50014653 (1975-05-01), None
patent: 52025734 (1977-07-01), None
patent: 55015460 (1980-04-01), None
patent: 56115747 (1981-09-01), None
patent: 61040270 (1986-09-01), None
patent: 01063570 (1989-03-01), None
patent: 04159266 (1992-06-01), None
patent: 10130241 (1998-05-01), None
patent: 01/181281 (1999-10-01), None
patent: WO 88/08418 (1988-11-01), None
patent: WO 92/12123 (1992-07-01), None
patent: WO 93/08799 (1993-05-01), None
patent: WO 94/27993 (1994-12-01), None
patent: WO 95/13262 (1995-05-01), None
patent: 9513262 (1995-05-01), None
patent: WO 97/30017 (1997-08-01), None
patent: WO 98/07681 (1998-02-01), None
patent: WO 98/08836 (1998-03-01), None
patent: WO 98/25608 (1998-06-01), None
patent: WO 99/11255 (1999-03-01), None
patent: 9919291 (1999-04-01), None
patent: WO 99/20275 (1999-04-01), None
patent: WO 99/62520 (1999-12-01), None
patent: WO 00/63161 (2000-10-01), None
patent: WO 01/40170 (2001-06-01), None
patent: WO 01/81340 (2001-11-01), None
patent: WO 02/02119 (2002-01-01), None
patent: WO 02/59077 (2002-01-01), None
patent: WO 02/14291 (2002-02-01), None
patent: WO 00/23409 (2004-04-01), None
patent: 6705655 (1967-01-01), None
U.S. Appl. No. 10/167,839, filed Oct. 14, 2002.
U.S. Appl. No. 10/685,183, filed Oct. 14, 2003.
Chemical Abstract DN 124:55567, also cityed as WO 9513262.
Chemical Abstract DN 130:281874, also cited as WO 9919291.
Witiak, et al., “Synthesis of Ethyl 6-Substituted-Chroman-and-Chromone-2-carboxylates. A Comparative Structure-Activity Study Employing the 6-Phenyl and Phenoxy Analogs in the Triton Hyperlipidemic Rat Model”, Journal Medical Chemistry, vol. 18, No. 9, pp. 934-942, 1975.
Karche, et al., “Electronic Effects in Migratory Groups . . . ”, Journal of Organic Chemistry, vol. 66, No. 19, pp. 6323-6332, 2001. (Abstract).
Poupardin, et al., “First approach to the cycloisodityrosine unit of Ra-IV”, Tetrahedron Letters, vol. 42, No. 8, pp. 1523-1526, 2001. (Abstract).
Manthey, et al., “Synthesis of Human Ultraviolet Filter Compounds . . . ”, Journal of Organic Chemistry, vol. 64, No. 11, pp. 3930-3933, 1999. (Abstract).
Wu, et al., “Improvement on the preparation of beta.-keto esters”, Huaxue Shiji, vol. 20, No. 6, pp. 376-377, 1998. (Abstract).
Wu, et al., “Total syntheses of furoguaiacin and related analogs”, Huaxue Yanjiu Yu Yingyoung, vol. 9, No. 6, pp. 595-599, 1997. (Abstract).
Fadnavis et al., “Baker's yeast mediated enantiospecific synthesis of anti-(2R,3R) . . . ”, Tetrahedron: Asymmetry, vol. 8, No. 24, pp. 4003-4006, 1997. (Abstract).
Wu, et al., “A modification of the Knorr oxidative coupling method for preparation of 1,4-diketones”, Synthetic Communications, vol. 27, No. 2, pp. 331-336, 1997. (Abstract).
Girard, et al. “Syntheses of the syn and anti.alpha.-amino-.beta.hydroxy acid of vancomycin . . . ”, Tetrahedron Letters, vol. 37, No. 44, pp. 7967-7970, 1996. (Abstract).
Smith, et al., “Synthesis and PAF antagonist activity of some 2,5-diaryltetrahydrofurans incorporating PAF-like functional groups”, European Journal of Medicinal Chemistry, vol. 31, No. 5, pp. 347-358, 1996. (Abstract).
Maruyama, et al., “A synthesis of (.+−.)-pinoresinol and its related compound using potassium persulfate (K2S208) oxidation of benzoylacetates”, Heterocycles, vol. 37, No. 2, pp. 839-845, 1994. (Abstract).
Rao, et al., “Studies on cyclodepsipeptides. Part II. The total synthesis of jaspamide and geodiamolide-D”, Tetrahedron Letters, vol. 34, No. 44, pp. 7085-7088, 1993. (Abstract).
Colotta, et al., “Tricyclic heteroaromatic systems . . . ”, Farmaco, vol. 46, No. 10, pp. 1139-1154, 1991. (Abstract).
Dillard et al., “(Phenylmethoxy) phenyl derivatives of w-oxo- and w-tetrazolylalkanoic acids . . . ”, J. Med. Chem., vol. 34, No. 9, pp. 2768-2778, 1991. (Abstract).
Bose, et al., “Synthesis of 4-phenylcoumarins fromDalbergia volubilisandExostema caribaeum”, Phytochemistry, vol. 30, No. 7, pp. 2438-2439, 1991. (Abstract).
Bose, et al., “Synthesis of 4-phenylcoumarins”, Indian J. Chem., Sect. B, vol. 29B, No. 5. pp. 422-444, 1990. (Abstract).
Colotta, et al., “Tricyclic heteroaromatic systems . . . ”, J. Med. Chem., vol. 33, No. 9, pp. 2646-2651, 1990. (Abstract).
Kameo, et al., “Studies on hypolipidemic agents, IV. 3-[4-Phenylthio) benzoyl] propionic acid derivatives”, Chem. Pharm. Bull., vol. 37, No. 5, pp. 1260-1267, 1989. (Abstract).
Colotta, et al., “Tricyclic heteroaromatic systems: synthesis . . . ”, J. Pharm. Sci., vol. 78, No. 3, pp. 239-242, 1989. (Abstract).
Tanaka, et al., “Total synthesis of coumarinolignans, aquillochin (cleomiscosin C) and cleomiscosin D”, Chem. Pharm. Bull., vol. 36, No. 10, pp. 3833-3837, 1988. (Abstract).
Parmar, et al., “Synthesis of new naturally occurring 4-phenyl-2H-1-benzopyran-2-ones”, Bull. Chem. Soc. Jpn., vol. 61, No. 6, pp. 2277-2279, 1988. (Abstract).
Colotta, et al., “The correct synthesis of 2,3-dihydro-2-aryl-4-R-[1] benzopyrano [4,3-c] pyrazole-3-ones”, Tetrahedron Letters, vol. 28, No. 43, pp. 5165-5168, 1987. (Abstract).
Tanaka, et al., “Total synthesis of daphneticin, a coumarinolignoid”, Chem. Pharm. Bull., vol. 34, No. 2 pp. 628-632, 1986. (Abstract).
Ahluwalia, et al., “Synthesis of stevenin and melanettin”, Symp. Pap- IUPAC Int. Symp. Chem. Nat. Prod., 11th, vol. 3, pp. 11-13, 1978. (Abstract).
Yamaguchi, “Degradation of protolignin with metallic sodium in liquid ammonia”, Ringyo Shikenjo Kenkyu Hokoku, vol. 281, pp. 1-78, 1976. (Abstract).
Okumura, et al., “Synthesis of chromone-3-carboxanilides”, Chem. Pharm. Bull., vol. 22, No. 2, pp. 331-336, 1974. (Abstract).
Von Wacek, et al., “Synthesis of methoxylated compounds for a comparative investigation of the stability of methyl ether groups”, Monatsh. Chem, vol. 97, No. 3, pp. 744-753, 1966. (Abstract).
Iwasa, et al., “The preparation of the biosynthetic precursor 3,7-dihydroxy-2, 6-dimethoxyphenthroindolizidine”, J. Nat. Prod., vol. 51, No. 1, pp. 172-175, 1998. (Abstract).
Wong, et al., “Wedelolactone and coumestan derivatives as new antihepatotoxic and antiphlogistic principles”, Arzneim.-Forsch., vol. 38, No. 5, pp. 661-665, 1988. (Abstract).
Witiak, et al., “Synthetic aci-reductiones. 3,4-Dihydroxy-2H-1-benzopyran-2-ones and their cis- and trans-4a, 5,6,7,8,8a-hexahydro diastereomers”, J. Med. Chem., vol. 31, No. 7, pp. 1437-1445, 1988. (Abstract).
Entzeroth, et al., “Preparation of 3- (3-indolyl) Lactic acids . . . ”, Liebigs Ann. Chem., No. 2, pp. 226-230, 1983. (Abstract).
Bhakuni, et al., Biosynthesis of tylophorine and tylophorinine, Tetrahedron, vol. 37, No. 2, pp. 401-407, 1981. (Abstract).
Naidu, et al., “Debenzylation by nickel-aluminum alloy”, J. Indian Inst. Sci., vol. 6
Sharma Shalini
von Borstel Reid W.
Kreisler Lewis J.
Patel Sudhaker B.
Raymond Richard L.
Wellstat Therapeutics Corporation
LandOfFree
Compounds for the treatment of metabolic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the treatment of metabolic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of metabolic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3516210